ASH 2025 | The safety and efficacy of rapcabtagene autoleucel in adult patients with R/R B-ALL
Pere Barba, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain, discusses the safety and efficacy of rapcabtagene autoleucel (YTB323) in adult patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) evaluated in a Phase I trial (NCT03960840). Dr Barba notes that the construct has a manageable safety profile, and the duration and depth of response appear promising. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Tomorrow I’m presenting the final results of the phase one study of YTB323 or rapcabtagene autoleucel in patients with ALL, relapsed and refractory. So these are adult patients and this construct that this has been presented also in this meeting in other diseases like lymphoma is a rapidly manufactured T-cell therapy and so we are studying this agent in 35 patients with relapse/refractory B-ALL...
Tomorrow I’m presenting the final results of the phase one study of YTB323 or rapcabtagene autoleucel in patients with ALL, relapsed and refractory. So these are adult patients and this construct that this has been presented also in this meeting in other diseases like lymphoma is a rapidly manufactured T-cell therapy and so we are studying this agent in 35 patients with relapse/refractory B-ALL. So basically what we see is that patients are very heavily pre-treated adult patients which have received inotuzumab, blinatumomab or both and we show a manageable safety profile with CRS and ICANS grade 3 or high below 20%, which is lower than with most of other products approved for this indication. And we also report a high 85% complete remission rate, including both complete and incomplete hematological recovery. And most important, all of these responses in evaluable patients are minimal residual disease negative. So we are not able to detect disease in these patients by flow cytometry. We also have shown a promising duration of response, especially for dose level three and four in this trial. So I think this is a very encouraging agent for ALL and I think we have new tools to treat this disease in these refractory and relapse patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
